查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439207

全球 PARP 抑制剂市场评估：按药物类型、应用、最终用户、分销管道、地区、机会和预测（2017-2031）

PARP Inhibitors Market Assessment, By Drug Type, By Application, By End-user, By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 227 Pages | 商品交期: 3-5个工作天内

价格

全球 PARP 抑制剂市场规模预计将从 2023 年的 64.4 亿美元成长到 2031 年的 175 亿美元，预测期内复合年增长率为 13.31%。

研发活动投资的增加和癌症盛行率的增加正在为市场创造利润丰厚的成长机会。

癌症盛行率的增加导致人们更加关注提高 PARP 抑制剂的功效，从而推动市场扩张。 根据美国癌症协会预测，2023年美国将新增癌症病例1,958,310例，癌症相关死亡人数将达609,820例。

根据美国国家乳癌基金会的数据，八分之一的女性将被诊断出罹患乳癌。 据估计，到 2023 年，将有 297,790 名女性和 2,800 名男性被诊断出患有侵袭性乳癌。 PARP 抑制剂可防止癌细胞修復受损的肿瘤 DNA。 奥拉帕尼用于治疗早期和转移性乳癌，他拉佐帕尼用于治疗转移性乳癌。

按地区划分，北美预计将占据较大的市场份额。 北美地区的 PARP 发展得益于该地区大公司的存在、熟练人才的供应、政府加强医疗保健行业的举措不断增加，以及研究机构和市场参与者对研发活动的投资增加。市场。 此外，美国的各个监管机构都专注于研究新型抗癌药物的功效并给予批准。

本报告调查了全球PARP 抑制剂市场，提供市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。我们编制分析、案例研究、竞争格局、主要公司简介等等。

目录

第一章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第四章全球PARP抑制剂市场展望

  • 市场规模/预测
  • 依药物类型
    • 奥拉帕尼
    • 尼拉帕尼
    • 鲁卡帕尼
    • 他拉佐帕尼
    • 维利帕尼
    • 其他
  • 依用途
    • 卵巢癌
    • 乳癌
    • 胰臟癌
    • 摄护腺癌
  • 按最终用户
    • 专科诊所
    • 医院
    • 家庭医疗护理
    • 其他
  • 按分销管道
    • 医院药房
    • 零售药局
    • 网路药局
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率

第五章全球 PARP 抑制剂市场前景：依地区划分

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 依药物类型
  • 依用途
  • 按最终用户
  • 按地区

第七章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑製成长的因素（问题、限制因素）

第 9 章监理架构与创新

  • 专利情况
  • 监理机关的核准
  • 创新/最新技术

第十章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第十三章主要公司展望

  • Pfizer, Inc.
  • GlaxoSmithKline Plc.
  • Genentech, Inc.
  • AbbVie Inc.
  • Sierra Oncology, Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Repare Therapeutic, Inc.
  • Karyopharm Therapeutics Inc.

第 14 章策略建议

第十五章关于我们公司/免责声明

Product Code: MX11043

Global PARP inhibitors market is projected to witness a CAGR of 13.31% during the forecast period 2024-2031, growing from USD 6.44 billion in 2023 to USD 17.5 billion in 2031F. Increased investments in research and development activities and the increasing prevalence of cancer are providing lucrative growth opportunities to the market.

Poly (ADP-ribose) polymerase (PARPs) catalyze the transfer of ADP-ribose in proteins. PARP1 and PARP2 mediate the DNA repair process and play an essential role in maintaining genomic stability. PARP inhibitors prevent cancer cells from repairing, causing their death. These drugs mostly avoid affecting healthy cells and target cancer cells.

The PARP enzyme has a wide range of functions in a cell, such as DNA damage response, regulation of transcription, and apoptosis. PARP inhibitors exploit the concept of synthetic lethality. In this lethal phenomenon, cell can survive an isolated genetic event, whereas cell death occurs in the case of co-occurrence of multiple genetic events. They target cancer cells that have a defective homologous recombination DNA repair pathway.

The growing emphasis on enhancing the efficacy of PARP inhibitors owing to the increasing prevalence of cancer further supports the market expansion. According to American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths were estimated to occur in the United States. The American Cancer Society estimated that in 2024, 12,740 women are expected to die due to ovarian cancer, and 19,680 new cases will be diagnosed in the United States.

Rising Cases of Breast Cancer Boost Market Demand

As per National Breast Cancer Foundation, one out of eight women will be diagnosed with breast cancer over the course of their lifetime. It was estimated that in 2023, 297,790 women and 2,800 men will get a diagnosis of invasive breast cancer. PARP inhibitors prevent the cancer cells from repairing damaged tumor DNA. Olaparib is used for the treatment of both early and metastatic breast cancer, and Talazoparib is used for the treatment of metastatic breast cancer.

Due to the growing prevalence of the disease, various organizations are providing additional funding to research institutions for better treatments and better prediction models for breast cancer. For instance, In November 2023, researchers from University of Washington, Seattle Children's Cancer Consortium and Fred Hutchinson received additional funding from Breast Cancer Research Foundation (BCRF) to continue working on their ongoing studies. The Vice President for Clinical Affairs and a medical oncologist, Davidson received funding for another year to research the expanded applications of PARP inhibitors.

Increasing Research Activities Support the PARP Inhibitors Market Growth

PARP inhibitors have shown promising results since their clinical applications and were the first clinically approved drugs that were developed based on synthetic lethality. The inhibitors have been approved for use as maintenance treatment for cancer patients with BRCA mutations. The continuation of innovative explorations is expected to support the development of potent drugs with novel mechanisms.

In 2023, the American Society of Clinical Oncology (ASCO) presented new updates on the utilization of PARP inhibitors for the treatment of ovarian cancer. Significant attempts are being made to combine PARP inhibitors with immune checkpoint inhibitors (ICIs) in patients suffering from advanced ovarian cancer. It was demonstrated in the DUO-O trial that the addition of maintenance Olaparib and anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor durvalumab to the standard of care prolongs progression free survival in cases on advanced ovarian cancer. PARP inhibitors present a promising avenue in the therapy for ovarian cancer. Ongoing research and development activities for novel agent combinations hold promise for future advancements.

North America Expected to Account for a Significant Market Share

The strong presence of various key players in the region, availability of skilled workforce, increasing government initiatives to strengthen the healthcare sector, and rising investments towards research and development activities by both research institutions and market players is supporting the expansion of the North America PARP inhibitors market. According to American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths were estimated to occur in the United States. Due to the surge in cases of cancer in the region, the requirement for advanced cancer therapeutics, including PARP inhibitors is increasing. The different regulatory bodies in the country are focusing on studying the effects of novel cancer treatments and granting them approvals.

In 2023, Pfizer, Inc., one of the leading pharmaceutical and biotechnology corporations in the United States, announced positive results from their phase 3 TALAPRO-2 study of TALZENNA (Talazoparib), an oral PARP inhibitor, combined with enzalutamide. They demonstrated a clinically meaningful and statistically significant improvement in radiographic progression free survival, with or without HRR gene mutations. The United States Food and Drug Administration (FDA) granted priority review of TALZENNA combined with enzalutamide for treatment of men with metastatic castration-resistant prostate cancer.

Preference for Olaparib Anticipated to Increase

Increasing adoption of Olaparib PARP inhibitors for treatment of pancreatic cancer, ovarian cancer, and both metastatic and early breast cancer is facilitating the market growth. In 2022, an article published in Cancer Discovery discussed the 5-year analysis of data, showing that the patients that received Olaparib for 2 years had a median progression free survival of 3.5 years longer than those who received placebo.

In January 2024, the post-hoc analysis of phase 3 PROpel trial (NCT03732820) presented at the 2024 Genitourinary Cancers Symposium confirmed that the treatment with frontline Olaparib and abiraterone acetate benefits patients with HRR mutated metastatic castration-resistant prostate cancer. The post-hoc exploratory analysis that examined the aggregate subgroups of non-BRCA-mutated, BRCA-mutate, non-HRR-mutated, and HRR-mutated disease further demonstrated favorable radiographic progression free survival outcomes with abiraterone plus Olaparib as opposed to abiraterone alone.

Retail Pharmacies Expected to Witness Significant Growth

The provision of branded as well as generic drugs, with other pharmaceutical products under one roof is bolstering the popularity of retail pharmacies in various regions across the globe. The pharmacists in these pharmacies are trusted counsel by many and often explain the side effects of different drugs to their customers. These pharmacies are an integral component of the healthcare ecosystem in various countries across the globe, accounting for a significant PARP inhibitors market share.

Meanwhile, online pharmacies are expected to rapidly expand in the coming years. The growth can be attributed to providing various benefits by online pharmacies, including privacy, discounts, fast shipping, delivery, convenience, and others. The online purchase of medicines from verified and legitimate internet pharmacies has become an accepted practice among various developed countries.

Future Market Scenario (2024 - 2031F)

Various clinical trials are underway to investigate the next generation of PARP inhibitors. PARP enzymes play different roles at different cell cycle stages, therefore, it is essential to understand the interaction network in the cells for the exploration of novel potential therapies.

Additional studies are required for determining if alternating drug combinations, including PARP inhibitors, anti-angiogenic agents, and immunotherapy are able to offer clinical benefits to patients suffering from ovarian cancer.

Recently, in RUBY Part 2 Phase 3 trial it was noted that the combination of Zejula (niraparib) and Jemperli (dostarlimab) significantly improved progression-free survival in recurrent or primary advanced endometrial cancer. The results have reinforced the development approach of using Jemperli in immuno-oncology-based combination therapies.

Key Players Landscape and Outlook

Key participants in global PARP inhibitors market include Pfizer, Inc., GlaxoSmithKline Plc., Genentech, Inc., AbbVie Inc., and Sierra Oncology, Inc. The rising investments towards research and development activities and increasing prevalence of different types of cancer is providing lucrative growth opportunities to the market.

In 2023, FDA approved Pfizer drug, Talazoparib (Talzenna) with enzalutamide for HRR gene mutated metastatic castration-resistant prostate cancer. The efficacy of the drug was evaluated in a multi-cohort, randomized, placebo-controlled, and double-blind trial that enrolled 399 patients with homologous recombination repair gene mutated metastatic castration-resistant prostate cancer.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global PARP Inhibitors Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Drug Type
    • 4.2.1. Olaparib
    • 4.2.2. Niraparib
    • 4.2.3. Rucaparib
    • 4.2.4. Talazoparib
    • 4.2.5. Veliparib
    • 4.2.6. Others
  • 4.3. By Application
    • 4.3.1. Ovarian Cancer
    • 4.3.2. Breast Cancer
    • 4.3.3. Pancreatic Cancer
    • 4.3.4. Prostate Cancer
  • 4.4. By End-user
    • 4.4.1. Specialty Clinics
    • 4.4.2. Hospitals
    • 4.4.3. Home Healthcare
    • 4.4.4. Others
  • 4.5. By Distribution Channel
    • 4.5.1. Hospital Pharmacies
    • 4.5.2. Retail Pharmacies
    • 4.5.3. Online Pharmacies
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. South America
    • 4.6.3. Europe
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East & Africa
  • 4.7. By Company Market Share (%), 2023

5. Global PARP Inhibitors Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Drug Type
      • 5.1.2.1. Olaparib
      • 5.1.2.2. Niraparib
      • 5.1.2.3. Rucaparib
      • 5.1.2.4. Talazoparib
      • 5.1.2.5. Veliparib
      • 5.1.2.6. Others
    • 5.1.3. By Application
      • 5.1.3.1. Ovarian Cancer
      • 5.1.3.2. Breast Cancer
      • 5.1.3.3. Pancreatic Cancer
      • 5.1.3.4. Prostate Cancer
    • 5.1.4. By End-user
      • 5.1.4.1. Specialty Clinics
      • 5.1.4.2. Hospitals
      • 5.1.4.3. Home Healthcare
      • 5.1.4.4. Others
    • 5.1.5. By Distribution Channel
      • 5.1.5.1. Hospital Pharmacies
      • 5.1.5.2. Retail Pharmacies
      • 5.1.5.3. Online Pharmacies
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Drug Type
      • 5.1.6.2.1. Olaparib
      • 5.1.6.2.2. Niraparib
      • 5.1.6.2.3. Rucaparib
      • 5.1.6.2.4. Talazoparib
      • 5.1.6.2.5. Veliparib
      • 5.1.6.2.6. Others
      • 5.1.6.3. By Application
      • 5.1.6.3.1. Ovarian Cancer
      • 5.1.6.3.2. Breast Cancer
      • 5.1.6.3.3. Pancreatic Cancer
      • 5.1.6.3.4. Prostate Cancer
      • 5.1.6.4. By End-user
      • 5.1.6.4.1. Specialty Clinics
      • 5.1.6.4.2. Hospitals
      • 5.1.6.4.3. Home Healthcare
      • 5.1.6.4.4. Others
      • 5.1.6.5. By Distribution Channel
      • 5.1.6.5.1. Hospital Pharmacies
      • 5.1.6.5.2. Retail Pharmacies
      • 5.1.6.5.3. Online Pharmacies
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Drug Type
  • 6.2. By Application
  • 6.3. By End-user
  • 6.4. By Distribution Channel
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. GlaxoSmithKline Plc.
  • 13.3. Genentech, Inc.
  • 13.4. AbbVie Inc.
  • 13.5. Sierra Oncology, Inc.
  • 13.6. Ono Pharmaceutical Co. Ltd.
  • 13.7. Johnson & Johnson Services, Inc.
  • 13.8. Jiangsu Hengrui Medicine Co., Ltd.
  • 13.9. Repare Therapeutic, Inc.
  • 13.10. Karyopharm Therapeutics Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 4. Global PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 5. Global PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global PARP Inhibitors Market Share (%), By Region, 2017-2031F
  • Figure 8. North America PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 11. North America PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 12. North America PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 13. North America PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America PARP Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 15. United States PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 18. United States PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 19. United States PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 20. United States PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 24. Canada PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 25. Canada PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 26. Canada PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 30. Mexico PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 31. Mexico PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 32. Mexico PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 36. Europe PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 37. Europe PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe PARP Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 43. Germany PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 44. Germany PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 45. Germany PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 49. France PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 50. France PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 51. France PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 55. Italy PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 56. Italy PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 57. Italy PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 61. United Kingdom PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 62. United Kingdom PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 63. United Kingdom PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 67. Russia PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 68. Russia PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 69. Russia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 73. Netherlands PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 74. Netherlands PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 75. Netherlands PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 79. Spain PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 80. Spain PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 81. Spain PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 85. Turkey PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 86. Turkey PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 87. Turkey PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 91. Poland PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 92. Poland PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 93. Poland PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 97. South America PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 98. South America PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 99. South America PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America PARP Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 104. Brazil PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 105. Brazil PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 106. Brazil PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 110. Argentina PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 111. Argentina PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 112. Argentina PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 116. Asia-Pacific PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 117. Asia-Pacific PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 118. Asia-Pacific PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific PARP Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 120. India PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 123. India PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 124. India PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 125. India PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 129. China PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 130. China PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 131. China PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 135. Japan PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 136. Japan PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 137. Japan PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 141. Australia PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 142. Australia PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 143. Australia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 147. Vietnam PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 148. Vietnam PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 149. Vietnam PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 153. South Korea PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 154. South Korea PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 155. South Korea PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 159. Indonesia PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 160. Indonesia PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 161. Indonesia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 165. Philippines PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 166. Philippines PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 167. Philippines PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 171. Middle East & Africa PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 172. Middle East & Africa PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 173. Middle East & Africa PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa PARP Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 178. Saudi Arabia PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 179. Saudi Arabia PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 180. Saudi Arabia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 184. UAE PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 185. UAE PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 186. UAE PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
  • Figure 190. South Africa PARP Inhibitors Market Share (%), By Application, 2017-2031F
  • Figure 191. South Africa PARP Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 192. South Africa PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023